200 related articles for article (PubMed ID: 38314061)
1. Population impact and cost-effectiveness of artificial intelligence-based diabetic retinopathy screening in people living with diabetes in Australia: a cost effectiveness analysis.
Hu W; Joseph S; Li R; Woods E; Sun J; Shen M; Jan CL; Zhu Z; He M; Zhang L
EClinicalMedicine; 2024 Jan; 67():102387. PubMed ID: 38314061
[TBL] [Abstract][Full Text] [Related]
2. Artificial Intelligence in Community-Based Diabetic Retinopathy Telemedicine Screening in Urban China: Cost-effectiveness and Cost-Utility Analyses With Real-world Data.
Lin S; Ma Y; Xu Y; Lu L; He J; Zhu J; Peng Y; Yu T; Congdon N; Zou H
JMIR Public Health Surveill; 2023 Feb; 9():e41624. PubMed ID: 36821353
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of artificial intelligence screening for diabetic retinopathy in rural China.
Huang XM; Yang BF; Zheng WL; Liu Q; Xiao F; Ouyang PW; Li MJ; Li XY; Meng J; Zhang TT; Cui YH; Pan HW
BMC Health Serv Res; 2022 Feb; 22(1):260. PubMed ID: 35216586
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of artificial intelligence-based diabetic retinopathy screening in rural China based on the Markov model.
Li H; Li G; Li N; Liu C; Yuan Z; Gao Q; Hao S; Fan S; Yang J
PLoS One; 2023; 18(11):e0291390. PubMed ID: 37971984
[TBL] [Abstract][Full Text] [Related]
5. Combined population genomic screening for three high-risk conditions in Australia: a modelling study.
Lacaze P; Marquina C; Tiller J; Brotchie A; Kang YJ; Merritt MA; Green RC; Watts GF; Nowak KJ; Manchanda R; Canfell K; James P; Winship I; McNeil JJ; Ademi Z
EClinicalMedicine; 2023 Dec; 66():102297. PubMed ID: 38192593
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness and cost-utility of traditional and telemedicine combined population-based age-related macular degeneration and diabetic retinopathy screening in rural and urban China.
Li R; Yang Z; Zhang Y; Bai W; Du Y; Sun R; Tang J; Wang N; Liu H
Lancet Reg Health West Pac; 2022 Jun; 23():100435. PubMed ID: 35355615
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of combined population-based screening for multiple blindness-causing eye diseases in China: a cost-effectiveness analysis.
Liu H; Li R; Zhang Y; Zhang K; Yusufu M; Liu Y; Mou D; Chen X; Tian J; Li H; Fan S; Tang J; Wang N
Lancet Glob Health; 2023 Mar; 11(3):e456-e465. PubMed ID: 36702141
[TBL] [Abstract][Full Text] [Related]
8. [Health economic evaluation of telemedicine diabetic retinopathy examination using a non-mydriatic fundus camera in China].
Fan JX; Zhang M; Zhao WY; Han Y; Hu WT; Jia HX; Sun XD
Zhonghua Yan Ke Za Zhi; 2023 Nov; 59(11):919-929. PubMed ID: 37936360
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness of artificial intelligence-assisted liquid-based cytology testing for cervical cancer screening in China.
Shen M; Zou Z; Bao H; Fairley CK; Canfell K; Ong JJ; Hocking J; Chow EPF; Zhuang G; Wang L; Zhang L
Lancet Reg Health West Pac; 2023 May; 34():100726. PubMed ID: 37283979
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation for medical artificial intelligence: accuracy vs. cost-effectiveness in a diabetic retinopathy screening case.
Wang Y; Liu C; Hu W; Luo L; Shi D; Zhang J; Yin Q; Zhang L; Han X; He M
NPJ Digit Med; 2024 Feb; 7(1):43. PubMed ID: 38383738
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation.
Su S; Wong WC; Zou Z; Cheng DD; Ong JJ; Chan P; Ji F; Yuen MF; Zhuang G; Seto WK; Zhang L
Lancet Glob Health; 2022 Feb; 10(2):e278-e287. PubMed ID: 35063115
[TBL] [Abstract][Full Text] [Related]
12. Optimising HIV pre-exposure prophylaxis and testing strategies in men who have sex with men in Australia, Thailand, and China: a modelling study and cost-effectiveness analysis.
Zhao R; Fairley CK; Cook AR; Phanuphak N; He S; Tieosapjaroen W; Chow EPF; Phillips TR; Jin Tan RK; Wei Y; Shen M; Zhuang G; Ong JJ; Zhang L
Lancet Glob Health; 2024 Feb; 12(2):e243-e256. PubMed ID: 38245115
[TBL] [Abstract][Full Text] [Related]
13. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease.
Pouwels XGLV; van Mil D; Kieneker LM; Boersma C; van Etten RW; Evers-Roeten B; Heerspink HJL; Hemmelder MH; Langelaan MLP; Thelen MHM; Gansevoort RT; Koffijberg H
EClinicalMedicine; 2024 Feb; 68():102414. PubMed ID: 38299045
[TBL] [Abstract][Full Text] [Related]
15. Cost-Utility Analysis of the Integrated Care Models for the Management of Hypertension Patients: A Quasi-Experiment in Southwest Rural China.
Ke X; Zhang L; Tang W
Front Public Health; 2021; 9():727829. PubMed ID: 34966712
[No Abstract] [Full Text] [Related]
16. Cost-utility analysis of screening for diabetic retinopathy in Japan: a probabilistic Markov modeling study.
Kawasaki R; Akune Y; Hiratsuka Y; Fukuhara S; Yamada M
Ophthalmic Epidemiol; 2015 Feb; 22(1):4-12. PubMed ID: 25517603
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Artificial Intelligence as a Decision-Support System Applied to the Detection and Grading of Melanoma, Dental Caries, and Diabetic Retinopathy.
Gomez Rossi J; Rojas-Perilla N; Krois J; Schwendicke F
JAMA Netw Open; 2022 Mar; 5(3):e220269. PubMed ID: 35289862
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov model.
Tang J; Liang Y; O'Neill C; Kee F; Jiang J; Congdon N
Lancet Glob Health; 2019 Jul; 7(7):e968-e978. PubMed ID: 31122906
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
